Log symptoms and side effects, check off daily protein, fluids and fiber, track strength training, plan for maintenance
or coming off, keep insurance and refill details straight, and walk into your next appointment with clear questions.
Free — no paid tierNo account or emailSaved on this deviceNo analytics · your notes are never uploadedExport to CSV any time
Red-flag symptoms: get help now, don’t just log them
This is a short summary of warnings in the FDA-approved Medication Guides for Wegovy (semaglutide) and
Zepbound (tirzepatide) (revised June 2026 and August 2026). It is not a complete list.
Other GLP-1 medicines (for example Ozempic, Mounjaro, Rybelsus, Saxenda, or tablet forms) have their own Medication Guides.
Compounded products don’t have an FDA-approved Medication Guide, so ask the pharmacy that filled yours what to watch for.
If your prescriber or your Medication Guide says something different, follow them. Not seeing a symptom here doesn’t mean you’re okay.
Call 911: signs of a serious allergic reaction. Swelling of your face, lips, tongue, or throat; problems breathing or swallowing;
severe rash or itching; fainting or feeling dizzy; a very rapid heartbeat. The Medication Guides say to stop using the medicine and get medical help right away.
Severe pain in your stomach area that won’t go away, with or without nausea or vomiting, sometimes felt from your abdomen through to your back
(possible pancreatitis). The Medication Guides say to stop using the medicine and call your healthcare provider right away.
If you can’t reach them quickly, go to urgent care or an emergency room.
Gallbladder warning signs: pain in your upper stomach, fever, yellowing of your skin or eyes, or clay-colored stools. Tell your healthcare provider right away.
Dehydration: nausea, vomiting, or diarrhea that doesn’t go away. The Medication Guides warn this can lead to kidney problems. Tell your healthcare provider right away.
Low blood sugar (more likely with insulin or a sulfonylurea): for example shakiness, sweating, confusion, fast heartbeat, blurred vision, or slurred speech.
Follow the plan your prescriber gave you. If someone passes out, call 911.
A lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath (thyroid tumor warning). Tell your healthcare provider.
Changes in vision (especially with type 2 diabetes), or a racing or pounding heartbeat at rest that lasts several minutes. Tell your healthcare provider.
Before any surgery, procedure, or sedation: tell every care team you take a GLP-1 medicine. The Medication Guides warn that food or liquid can get into the lungs during anesthesia or deep sedation.
Took too much? The Medication Guides say to call your healthcare provider or Poison Help at 1-800-222-1222, or go to the nearest emergency room right away.
Never use this tool, a chart, or a website to work out a dose or “units.” Ask the pharmacist who filled your prescription.
In crisis, or thinking about suicide or self-harm? Call or text 988, or chat at 988lifeline.org, any time.
(This is a general safety resource. FDA asks patients to tell their health care professional about new or worsening depression, suicidal thoughts, or unusual changes in mood.)
These are general reference numbers from published guidance, not a prescription.
Your needs depend on your health (for example, kidney disease can change protein advice). Ask your clinician or a registered dietitian what is right for you.
A 2025 joint advisory from four nutrition and obesity-medicine societies notes: the general adult recommended daily allowance is
0.8 g of protein per kg of body weight per day; higher targets such as 1.2–1.6 g/kg/day “have also been proposed during active weight reduction”;
and it is unclear whether these should be based on actual, adjusted, or ideal body weight — using actual weight can overestimate needs.
Source: Mozaffarian et al., Am J Clin Nutr 2025.
Today’s checklist
Tick what you did today. It resets each day and is saved only in this browser.
Fiber: MedlinePlus lists 21–38 grams a day as the general recommendation for adults (most Americans eat about 16 g).
The 2025 advisory suggests increasing fiber gradually, and that avoiding fatty or high-fiber foods in the first few days of treatment may ease nausea.
MedlinePlus fiber · advisory.
Fluids: the Wegovy and Zepbound Medication Guides say it is important to drink fluids to help reduce the chance of dehydration.
Ask your clinician how much is right for you — some heart and kidney conditions require fluid limits.
Wegovy label · Zepbound label.
This week’s activity
The CDC’s general guideline for adults is at least 150 minutes of moderate activity a week, plus
muscle-strengthening on 2 or more days that works all major muscle groups (legs, hips, back, abdomen, chest, shoulders, arms).
Source: CDC. Ask your clinician before starting or increasing exercise if you have health conditions.
Muscle-preservation checklist
GLP-1 weight loss can include loss of muscle and bone. The 2025 advisory emphasizes preserving muscle and bone through
resistance training and appropriate diet, and suggests muscle strength and body-composition assessment as part of care.
Source. These are prompts to discuss — not an exercise prescription.
Check-in dates
If a change date is set, here are 30 / 60 / 90-day check-in reminders to review your log and plan with your care team.
What the research says (general, not about you)
NIDDK: you will probably regain some weight after stopping weight-management medicine; healthy eating habits and more physical activity may help you regain less. NIDDK
STEP 1 trial extension: one year after stopping semaglutide 2.4 mg and the trial’s lifestyle program, participants regained about two-thirds of their prior weight loss on average. Wilding et al., 2022
SURMOUNT-4 trial: people switched from tirzepatide to placebo regained substantial weight, while those who continued maintained their loss. Aronne et al., JAMA 2024
The 2025 advisory notes individual responses vary widely, and that nutrition priorities after stopping still need more study. Advisory
Questions to ask your health plan, pharmacy, or benefits team
Prior authorization means approval from a health plan that may be required before you fill a prescription for it to be covered
(HealthCare.gov). NIDDK notes that some, but not all, plans cover these medicines — contact your plan to find out (NIDDK).
This is a checklist, not insurance advice.
My coverage & refill details
Stay safe: the FDA recommends getting a prescription from your doctor and filling it at a
state-licensed pharmacy. It warns about unapproved, counterfeit, and “for research purposes only” versions, and red flags such as sellers
that don’t require a prescription, prices that seem too good to be true, or medicine that looks different from what you received before.
FDA. Talk to your prescriber before switching products.
Pick what you want to talk about
My questions
Choose topics and select “Make my question list”.
How to use it
1
Log your days
In the Daily log tab, write down how you felt, any symptoms or side effects, and notes. “Add 3 sample days” shows how it looks first.
2
Keep the admin in one place
In Insurance & refills, keep prior-auth numbers, expiry and refill dates, and who you spoke with.
3
Bring questions to your visit
In Questions for my prescriber, pick topics, make your list, and print or download it for your appointment.
Why this exists
In the CAMP study of adults prescribed semaglutide or tirzepatide at one large U.S. academic health system (2,628 surveyed),
88% said they got medication instructions, but only 27% got a referral to any other service, such as nutrition counseling.
Among those who stopped, the most common reason was that insurance stopped covering it (37.7%). CAMP study, 2026.
Other surveys point the same way: 68% of 2,000 GLP-1 users said cost influenced whether they started or continued (Navitus),
and more than 1 in 3 of 585 users had trouble filling a prescription, most often because it was out of stock (GoodRx/YouGov).
That leaves a lot to keep track of on your own. GLP-1 Support is a free, private place to keep those notes together and bring them to your prescriber.
It organizes; it doesn’t advise. Not medical advice. Talk to your prescriber.
Where your information goes
What you type stays on this device. It’s saved in this browser’s local storage. It isn’t sent to me or anyone else, and I can’t see it or recover it.
There’s no account and no sign-in, and this tool uses no cookies, analytics, ads, or third-party scripts. The page’s security settings block its code from sending data over the network.
Loading the page does involve a web host. Your browser downloads this page from GitHub Pages, which, like most hosts, logs visitors’ IP addresses for security purposes
(GitHub’s explanation). I don’t receive those logs.
Your notes leave this browser only if you choose. Exporting a CSV, downloading or printing your plan or questions, or copying text creates ordinary, unencrypted copies outside the browser. Store and share them carefully.
Who else might see it: anyone who can use this browser profile on this device, and browser extensions you’ve installed. On a shared device, use Clear my data.
It can disappear. Clearing your browsing data or using a private window can erase it, so export a copy if you want to keep it.
This is a personal notebook, not a medical record, and it isn’t connected to your doctor, pharmacy, or health plan.
If something on this page breaks, tell me on GitHub.
Please redact secrets before you post, and don’t include personal health information. This is not medical advice — questions about treatment belong with your prescriber.
Sources
Wegovy (semaglutide) prescribing information and Medication Guide, via DailyMed (U.S. National Library of Medicine).
dailymed.nlm.nih.gov
Zepbound (tirzepatide) prescribing information and Medication Guide, via DailyMed.
dailymed.nlm.nih.gov
Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine,
the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344–367 (corrigendum published 2026).
Full text (PMC) ·
doi
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022.
PubMed 35441470
Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
PubMed 38078870
U.S. FDA Drug Safety Communication (January 13, 2026): FDA requests removal of the suicidal behavior and ideation warning from GLP-1 receptor agonist labels.
fda.gov
U.S. FDA: FDA alerts health care providers, compounders and patients of dosing errors associated with compounded semaglutide.
fda.gov
988 Suicide & Crisis Lifeline (a general crisis line). 988lifeline.org
Tewksbury C, et al. Patient characteristics and early experiences with anti-obesity medications: the CAMP study. Front Nutr. Published September 8, 2026.
doi:10.3389/fnut.2026.1931188
Navitus Health Solutions Pulse Survey (2,000 U.S. adults who took a GLP-1 in the last two years; Pollfish, January 2026). Press release, February 24, 2026.
navitus.com
GoodRx Research survey via YouGov (August–October 2025; 585 current or former GLP-1 users for weight loss, weighted), as reported by Stacker, May 22, 2026.
stacker.com
Content last reviewed: September 30, 2026, by Arup Kumar Banerjee. Checked against: Wegovy Medication Guide (revised 06/2026)
and Zepbound Medication Guide (revised 08/2026) on DailyMed; FDA Drug Safety Communication on GLP-1 RA labeling (Jan. 13, 2026); FDA alert on compounded semaglutide dosing errors;
MedlinePlus; NIDDK; CDC Adult Activity: An Overview; HealthCare.gov; Mozaffarian et al., Am J Clin Nutr 2025 (CC BY-NC-ND 4.0).
Guidance and labels change. Found an error?Report it on GitHub
(please don’t include personal health information). Your prescriber and your product’s current Medication Guide come first.
Trademarks and endorsements: Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company.
Other product names are trademarks of their owners. Names are used only to identify the medicines. GLP-1 Support is not affiliated with, sponsored by, or endorsed by any drug maker.
References to FDA, NIH (including NLM, MedlinePlus, and NIDDK), CDC, HealthCare.gov, or any other agency or organization don’t imply their endorsement; their materials are available free on their own websites.
The 2025 nutrition advisory is quoted under its CC BY-NC-ND 4.0 license.